Drug Discovery in Cancer Epigenetics - Couverture rigide

Livre 3 sur 39: Translational Epigenetics
 
9780128022085: Drug Discovery in Cancer Epigenetics

Synopsis

Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as biomarkers for diagnosis, prognosis or therapy prediction. Most importantly, epigenetic modifications are reversible and epigenetic players are found mutated in different cancers; therefore, they provide attractive therapeutic targets. There has been great interest in developing and testing epigenetic drugs, which inhibit DNA methyltransferases, histone modifying enzymes or chromatin reader proteins. The first few drugs are already FDA approved and have made their way into clinical settings. This book provides a comprehensive summary of the epigenetic drugs currently available and aims to increase awareness in this area to foster more rapid translation of epigenetic drugs into the clinic.

Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.

À propos des auteurs

Dr. Gerda Egger is an Associate Professor of Epigenetics at the Clinical Institute of Pathology, Medical University of Vienna.

Dr. Paola Barbara Arimondo is the Director of the Unité de Service et de Recherche (USR n°3388) entitled "Epigenetic Targeting of Cancer -ETaC-" which brings together basic and applied research - a joint laboratory of the Institut de Recherche Pierre Fabre (IRPF) and the CNRS. She is extremely experienced in researching regulatory pharmaceuticals and cancer epigenetics.

Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.